Literature DB >> 16407835

Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway.

J Chung1, A M Roberts, J Chow, N Coady-Osberg, M Ohh.   

Abstract

The von Hippel-Lindau (VHL) tumour suppressor gene encodes a substrate-specifying component of an E3 ubiquitin ligase that targets hypoxia-inducible factor (HIF) alpha subunits for degradation under normoxia. The VHL protein is composed of an N-terminal HIFalpha-binding beta domain and a C-terminal alpha domain, which is necessary and sufficient for the formation of the E3 multiprotein enzyme. A large number of disease-causing mutations in either the alpha or beta domain renders HIFalpha stable irrespective of oxygen tension, leading to the upregulation of numerous HIF-target genes, such as GLUT1 and VEGF. Here, we show that VHL forms a self-associated complex in vivo, but not in vitro, and demonstrate that coexpression of two different VHL missense mutants -- one in the alpha domain and the other in the beta domain -- restores HIF-mediated gene expression profile. These findings indicate that VHL homotypic complexes can function in vivo in a complementary fashion to target HIFalpha for ubiquitin-mediated proteolysis, and potentially explain why VHL-associated tumours with a missense mutation-carrying VHL allele is almost invariably accompanied by a second VHL allele harbouring a gross truncation or deletion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407835     DOI: 10.1038/sj.onc.1209328

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein.

Authors:  Zhiyong Ding; Peter German; Shanshan Bai; A Srinivas Reddy; Xian-De Liu; Mianen Sun; Lijun Zhou; Xiaohua Chen; Xiaobei Zhao; Chengbiao Wu; Shuxing Zhang; Gordon B Mills; Eric Jonasch
Journal:  Cancer Res       Date:  2014-04-22       Impact factor: 12.701

2.  Proteostasis modulators prolong missense VHL protein activity and halt tumor progression.

Authors:  Chunzhang Yang; Kristin Huntoon; Alexander Ksendzovsky; Zhengping Zhuang; Russell R Lonser
Journal:  Cell Rep       Date:  2013-01-10       Impact factor: 9.423

3.  Hypoxia-inducible factor-1α (HIF-1α) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions.

Authors:  Tingfang Yi; Evangelos Papadopoulos; Patrick R Hagner; Gerhard Wagner
Journal:  J Biol Chem       Date:  2013-05-10       Impact factor: 5.157

4.  Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.

Authors:  Ryan C Russell; Roxana I Sufan; Bing Zhou; Pardeep Heir; Severa Bunda; Stephanie S Sybingco; Samantha N Greer; Olga Roche; Samuel A Heathcote; Vinca W K Chow; Lukasz M Boba; Terri D Richmond; Michele M Hickey; Dwayne L Barber; David A Cheresh; M Celeste Simon; Meredith S Irwin; William Y Kim; Michael Ohh
Journal:  Nat Med       Date:  2011-06-19       Impact factor: 53.440

5.  Cullin-RING ubiquitin ligases: global regulation and activation cycles.

Authors:  Dimple R Bosu; Edward T Kipreos
Journal:  Cell Div       Date:  2008-02-18       Impact factor: 5.130

6.  Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer.

Authors:  Feng-Feng Cai; Cheng Xu; Xin Pan; Lu Cai; Xiao-Yan Lin; Su Chen; Ewelina Biskup
Journal:  Oncotarget       Date:  2016-11-22

Review 7.  The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis.

Authors:  Petra Hudler; Mojca Urbancic
Journal:  Genes (Basel)       Date:  2022-02-17       Impact factor: 4.096

8.  Biophysical and functional study of CRL5Ozz, a muscle specific ubiquitin ligase complex.

Authors:  Yvan Campos; Amanda Nourse; Ajay Tanwar; Ravi Kalathur; Erik Bonten; Alessandra d'Azzo
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.996

9.  Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein.

Authors:  Giovanni Minervini; Gabriella M Mazzotta; Alessandro Masiero; Elena Sartori; Samantha Corrà; Emilio Potenza; Rodolfo Costa; Silvio C E Tosatto
Journal:  Sci Rep       Date:  2015-07-27       Impact factor: 4.379

10.  E2F3 upregulation promotes tumor malignancy through the transcriptional activation of HIF-2α in clear cell renal cell carcinoma.

Authors:  Yu Gao; Hongzhao Li; Xin Ma; Yang Fan; Dong Ni; Yu Zhang; Qingbo Huang; Kan Liu; Xintao Li; Lei Wang; Yuanxin Yao; Qing Ai; Xu Zhang
Journal:  Oncotarget       Date:  2016-07-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.